Merrell Dow's Sabril (vigabatrin or gamma vinyl GABA)
Merrell Dow's Sabril (vigabatrin or gamma vinyl GABA): Company's request to re-initiate clinical trials with the anticonvulsant drug will be reviewed Nov. 20 by FDA's Peripheral and Central Nervous System Drugs Advisory Committee. Sabril was reviewed by the committee in 1984 and again in 1985 after brain vacuoles were detected in monkeys sacrificed for a toxicity study. The committee recommended that Merrell Dow stop enrolling new human subjects in trials with the drug until it could be demonstrated that any pathological changes were reversible. Patients already on the drug were allowed to continue. Merrell Dow will submit further animal studies and additional human data obtained from foreign trials. Meeting begins at 9 a.m. in Parklawn Conference Rooms D and E.
You may also be interested in...
Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization.
European Commission medtech news all but dried up in September. But the UK’s Brexit news and implications for medtech has given EU and UK medtech stakeholders enough to ponder.
A new frontier for IO therapies in gastric/gastroesophageal cancers is opening up on positive data for two leading checkpoint inhibitors in first-line advanced disease where BMS’s Opdivo looks likely to have an advantage over Merck & Co’s Keytruda.